Becton, Dickinson and (NYSE:BDX) will announce its earnings results before the market opens on Thursday, May 6th. Analysts expect the company to announce earnings of $3.05 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Becton, Dickinson and (NYSE:BDX) last released its earnings results on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.14 by $1.41. The company had revenue of $5.32 billion for the quarter, compared to analyst estimates of $4.87 billion. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.65 EPS. On average, analysts expect Becton, Dickinson and to post $13 EPS for the current fiscal year and $13 EPS for the next fiscal year.
NYSE:BDX opened at $251.52 on Wednesday. The firm has a market cap of $73.08 billion, a price-to-earnings ratio of 92.13, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. The company has a current ratio of 1.54, a quick ratio of 1.07 and a debt-to-equity ratio of 0.72. The company’s 50-day moving average is $248.20 and its two-hundred day moving average is $246.57. Becton, Dickinson and has a 12-month low of $219.50 and a 12-month high of $284.97.
A number of research analysts have recently commented on the stock. Citigroup upped their price objective on shares of Becton, Dickinson and from $273.00 to $280.00 and gave the company a “neutral” rating in a research note on Friday, February 5th. Raymond James upped their price objective on shares of Becton, Dickinson and from $270.00 to $282.00 and gave the company an “outperform” rating in a research note on Friday, January 29th. TheStreet raised shares of Becton, Dickinson and from a “c+” rating to an “a-” rating in a research report on Thursday, February 4th. Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 target price for the company. in a research report on Wednesday, January 13th. Finally, Piper Sandler increased their target price on shares of Becton, Dickinson and from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 4th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Becton, Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $281.08.
About Becton, Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: Key terms to understand channel trading
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.